Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US
FDA Approval In June 2020 Hung Up By IP Barriers
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.
